TrialBritish journal of clinical pharmacology2017

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.

Patrick F Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.